X4 Pharmaceuticals (XFOR) Total Non-Current Liabilities (2017 - 2025)

X4 Pharmaceuticals' Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $104.2 million for Q4 2025.

• Quarterly Total Non-Current Liabilities fell 5.77% year-over-year to $104.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $104.2 million (down 5.77% YoY) and the FY2025 annual result came in at $104.2 million, down 5.77% from the prior year.
• Total Non-Current Liabilities was $104.2 million for Q4 2025 at X4 Pharmaceuticals, up from $101.0 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $115.2 million in Q2 2024 and bottomed at $49.3 million in Q1 2022.
• A 5-year average of $80.5 million and a median of $81.1 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities soared 106.17% — and 2025, when it declined 12.61%.
• X4 Pharmaceuticals' Total Non-Current Liabilities stood at $52.8 million in 2021, then increased by 13.78% to $60.0 million in 2022, then surged by 34.05% to $80.5 million in 2023, then jumped by 37.36% to $110.5 million in 2024, then slipped by 5.77% to $104.2 million in 2025.
• Business Quant data shows XFOR's Total Non-Current Liabilities at $104.2 million in Q4 2025, $101.0 million in Q3 2025, and $100.7 million in Q2 2025.